"Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial" by Lauren Carcas

Selected Works of Lauren Carcas

Follow Contact

Article

Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial

Annals of Oncology (2020)

Lauren Carcas, Baptist Health South Florida
C H Barcenas
Philip Hurvitz
J A Di Palma
R Bose
A J Chien
N Iannotti
G Marx
A Brufsky
A Litvak
E Ibrahim
R H Alvarez
M Ruiz-Borrego
N Chan
Y Manalo
Andrea Kellum
M Trudeau
M Thirlwell
J Garcia Saenz
D Hunt
R Bryce
L McCulloch
H S Rugo
D Tripathy
A Chan
CONTROL Study Investigators

Link

Disciplines

Medicine and Health Sciences

Publication Date

September, 2020

DOI

10.1016/j.annonc.2020.05.012

Citation Information

Lauren Carcas, C H Barcenas, Philip Hurvitz, J A Di Palma, et al.. "Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial" Annals of Oncology Vol. 31 Iss. 9 (2020) p. 1223 - 1230
Available at: http://works.bepress.com/lauren-carcas/17/